• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Dendreon appoints three to executive team

Dendreon appoints three to executive team

March 14, 2012
CenterWatch Staff

Seattle, Wash.-based Dendreon has appointed three new members to its executive team:

Joe DePinto is joining Dendreon as executive vice president, global commercial operations and will be responsible for all sales, marketing, and market access teams in the U.S. and globally. He has spent the last 20 years commercializing and developing oncology products, his experience includes sales, marketing, strategic accounts, market access, and product development on the R&D side. DePinto has held other vice president positions at ImClone Systems (subsidiary of Eli Lilly), Abraxis Bioscience and Ortho Biotech Products.

Robert S. Poulton was named executive vice president, technical operations and will oversee Dendreon's global manufacturing, operations, logistics and quality functions. He brings more than two decades of manufacturing and operational experience to the executive team, having previously served Dendreon as its global head of quality. Previously, Poulton served in a number of vice president positions at Wyeth, GlaxoSmithKline and SmithKline Beecham.

Christine Mikail was appointed as executive vice president, corporate development, general counsel, secretary and will be responsible for legal, corporate development and government affairs at Dendreon. She has experience in high-growth business development, complex transaction structuring and negotiation, intellectual property and patent portfolio management, regulatory and clinical strategy, as well as public company representation. Mikail has served in vice president positions at Savient Pharmaceuticals and ImClone Systems (subsidiary of Eli Lilly), and has worked at the law firms of Reed Smith LLP, Lowenstein Sandler PC and Wilmer Hale.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing